Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Report: Developing Opportunities within AG Mortgage Investment Trust, Associated Banc-Corp, Reata Pharmaceuticals, Nathan's Famous, United Fire Group, and Intercept Pharmaceuticals — Future Expectations, Projections Moving into 2018

MITT, ASB, NATH, UFCS

NEW YORK, May 18, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of AG Mortgage Investment Trust, Inc. (NYSE:MITT), Associated Banc-Corp (NYSE:ASB), Reata Pharmaceuticals, Inc. (NASDAQ:RETA), Nathan's Famous, Inc. (NASDAQ:NATH), United Fire Group, Inc (NASDAQ:UFCS), and Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT), including updated fundamental summaries, consolidated fiscal reporting, and fully-qualified certified analyst research.

Complimentary Access: Research Reports

Full copies of recently published reports are available to readers at the links below.

MITT DOWNLOAD: http://Fundamental-Markets.com/register/?so=MITT
ASB DOWNLOAD:
http://Fundamental-Markets.com/register/?so=ASB
RETA DOWNLOAD:
http://Fundamental-Markets.com/register/?so=RETA
NATH DOWNLOAD:
http://Fundamental-Markets.com/register/?so=NATH
UFCS DOWNLOAD:
http://Fundamental-Markets.com/register/?so=UFCS
ICPT DOWNLOAD:
http://Fundamental-Markets.com/register/?so=ICPT

(You may have to copy and paste the link into your browser and hit the [ENTER] key)

The new research reports from Fundamental Markets, available for free download at the links above, examine AG Mortgage Investment Trust, Inc. (NYSE:MITT), Associated Banc-Corp (NYSE:ASB), Reata Pharmaceuticals, Inc. (NASDAQ:RETA), Nathan's Famous, Inc. (NASDAQ:NATH), United Fire Group, Inc (NASDAQ:UFCS), and Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) on a fundamental level and outlines the overall demand for their products and services in addition to an in-depth review of the business strategy, management discussion, and overall direction going forward. Several excerpts from the recently released reports are available to today's readers below.

-----------------------------------------

Important Notice: the following excerpts are not designed to be standalone summaries and as such, important information may be missing from these samples. Please download the entire research report, free of charge, to ensure you are reading all relevant material information. All information in this release was accessed May 16th, 2018. Percentage calculations are performed after rounding. All amounts in millions (MM), except per share amounts.

-----------------------------------------

AG MORTGAGE INVESTMENT TRUST, INC. (MITT) REPORT OVERVIEW

AG Mortgage Investment Trust's Recent Financial Performance

For the three months ended March 31st, 2018 vs March 31st, 2017, AG Mortgage Investment Trust reported revenue of $39.36MM vs $27.96MM (up 40.76%) and basic earnings per share $0.17 vs $0.79 (down 78.48%). For the twelve months ended December 31st, 2017 vs December 31st, 2016, AG Mortgage Investment Trust reported revenue of $128.85MM vs $123.01MM (up 4.75%) and basic earnings per share $3.77 vs $1.80 (up 109.44%). AG Mortgage Investment Trust is expected to report earnings on August 14th, 2018. The report will be for the fiscal period ending June 30th, 2018.

To read the full AG Mortgage Investment Trust, Inc. (MITT) report, download it here: http://Fundamental-Markets.com/register/?so=MITT

-----------------------------------------

ASSOCIATED BANC-CORP (ASB) REPORT OVERVIEW

Associated Banc-Corp's Recent Financial Performance

For the three months ended March 31st, 2018 vs March 31st, 2017, Associated Banc-Corp reported interest income of $261.53MM vs $206.79MM (up 26.47%) and basic earnings per share $0.41 vs $0.36 (up 13.89%). For the twelve months ended December 31st, 2017 vs December 31st, 2016, Associated Banc-Corp reported interest income of $886.61MM vs $791.57MM (up 12.01%) and basic earnings per share $1.45 vs $1.27 (up 14.17%). Associated Banc-Corp is expected to report earnings on July 19th, 2018. The report will be for the fiscal period ending June 30th, 2018. The reported EPS for the same quarter last year was $0.36. The estimated EPS forecast for the next fiscal year is $2.06 and is expected to report on January 24th, 2019.

To read the full Associated Banc-Corp (ASB) report, download it here: http://Fundamental-Markets.com/register/?so=ASB

-----------------------------------------

REATA PHARMACEUTICALS, INC. (RETA) REPORT OVERVIEW

Reata Pharmaceuticals' Recent Financial Performance

For the three months ended March 31st, 2018 vs March 31st, 2017, Reata Pharmaceuticals reported revenue of $32.39MM vs $12.73MM (up 154.41%) and basic earnings per share $0.16 vs -$0.32. For the twelve months ended December 31st, 2017 vs December 31st, 2016, Reata Pharmaceuticals reported revenue of $48.06MM vs $49.86MM (down 3.61%) and basic earnings per share -$1.99 vs -$0.31. Reata Pharmaceuticals is expected to report earnings on August 13th, 2018. The report will be for the fiscal period ending June 30th, 2018. The reported EPS for the same quarter last year was -$0.52. The estimated EPS forecast for the next fiscal year is -$2.97 and is expected to report on March 1st, 2019.

To read the full Reata Pharmaceuticals, Inc. (RETA) report, download it here: http://Fundamental-Markets.com/register/?so=RETA

-----------------------------------------

NATHAN'S FAMOUS, INC. (NATH) REPORT OVERVIEW

Nathan's Famous' Recent Financial Performance

For the three months ended December 31st, 2017 vs December 31st, 2016, Nathan's Famous reported revenue of $22.08MM vs $19.94MM (up 10.76%) and basic earnings per share -$0.90 vs $0.17. For the twelve months ended March 31st, 2017 vs March 31st, 2016, Nathan's Famous reported revenue of $96.65MM vs $100.89MM (down 4.20%) and basic earnings per share $1.79 vs $1.38 (up 29.71%). Nathan's Famous is expected to report earnings on June 8th, 2018. The report will be for the fiscal period ending March 31st, 2018.

To read the full Nathan's Famous, Inc. (NATH) report, download it here: http://Fundamental-Markets.com/register/?so=NATH

-----------------------------------------

UNITED FIRE GROUP, INC (UFCS) REPORT OVERVIEW

United Fire Group's Recent Financial Performance

For the three months ended March 31st, 2018 vs March 31st, 2017, United Fire Group reported revenue of $250.80MM vs $251.28MM (down 0.19%) and basic earnings per share $1.84 vs $0.78 (up 135.90%). For the twelve months ended December 31st, 2017 vs December 31st, 2016, United Fire Group reported revenue of $1,052.74MM vs $996.36MM (up 5.66%) and basic earnings per share $2.03 vs $1.97 (up 3.05%). United Fire Group is expected to report earnings on August 1st, 2018. The report will be for the fiscal period ending June 30th, 2018.

To read the full United Fire Group, Inc (UFCS) report, download it here: http://Fundamental-Markets.com/register/?so=UFCS

-----------------------------------------

INTERCEPT PHARMACEUTICALS, INC. (ICPT) REPORT OVERVIEW

Intercept Pharmaceuticals' Recent Financial Performance

For the three months ended March 31st, 2018 vs March 31st, 2017, Intercept Pharmaceuticals reported revenue of $35.96MM vs $21.05MM (up 70.86%) and basic earnings per share -$3.22 vs -$3.61. For the twelve months ended December 31st, 2017 vs December 31st, 2016, Intercept Pharmaceuticals reported revenue of $130.96MM vs $24.95MM (up 424.85%) and basic earnings per share -$14.38 vs -$16.74. Intercept Pharmaceuticals is expected to report earnings on July 30th, 2018. The report will be for the fiscal period ending June 30th, 2018. The reported EPS for the same quarter last year was -$3.46. The estimated EPS forecast for the next fiscal year is -$8.44 and is expected to report on February 13th, 2019.

To read the full Intercept Pharmaceuticals, Inc. (ICPT) report, download it here: http://Fundamental-Markets.com/register/?so=ICPT

-----------------------------------------

ABOUT FUNDAMENTAL MARKETS

Fundamental Markets serves thousands of members and have provided research through some of the world's leading brokerages for over a decade–and continue to be one of the best information sources for investors and investment professionals worldwide. Fundamental Markets' roster boasts decades of financial experience and includes top financial writers, FINRA® BrokerCheck® certified professionals with current and valid CRD® number designations, as well as Chartered Financial Analyst® (CFA®) designation holders, to ensure up to date factual information for active readers on the topics they care about.

REGISTERED MEMBER STATUS

Fundamental Markets' oversight and audit staff are registered analysts, brokers, and/or financial advisers ("Registered Members") working within Equity Research, Media, and Compliance departments. Fundamental Markets' roster includes qualified CFA® charterholders, licensed securities attorneys, and registered FINRA® members holding duly issued CRD® numbers. Current licensed status of several Registered Members at Fundamental Markets have been independently verified by an outside audit firm, including policy and audit records duly executed by Registered Members. Complaints, concerns, questions, or inquiries regarding this release should be directed to Fundamental Markets' Compliance department by Phone, at +1 667-401-0010, or by E-mail at compliance@Fundamental-Markets.com.

LEGAL NOTICES

Information contained herein is not an offer or solicitation to buy, hold, or sell any security. Fundamental Markets, Fundamental Markets members, and/or Fundamental Markets affiliates are not responsible for any gains or losses that result from the opinions expressed. Fundamental Markets makes no representations as to the completeness, accuracy, or timeliness of the material provided and all materials are subject to change without notice. Fundamental Markets has not been compensated for the publication of this press release by any of the above mentioned companies. Fundamental Markets is not a financial advisory firm, investment adviser, or broker-dealer, and does not undertake any activities that would require such registration. For our full disclaimer, disclosure, and terms of service please visit our website.

Media Contact:
Andrew Duffie, Media Department
Office: +1 667-401-0010
E-mail: media@Fundamental-Markets.com 

© 2018 Fundamental Markets. All Rights Reserved. For republishing permissions, please contact a partner network manager at partnership@Fundamental-Markets.com.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

FINRA®, BrokerCheck®, and CRD® are registered trademarks owned by Financial Industry Regulatory Authority, Inc.

Primary Logo